177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.

UNLABELLED Gastrin-releasing peptide receptors (GRP-R) are upregulated in many cancers, including prostate, breast, and lung. We describe a new radiolabeled bombesin (BBN) analog for imaging and systemic radiotherapy that has improved pharmacokinetics (PK) and better retention of radioactivity in the tumor. METHODS DO3A-CH2CO-G-4-aminobenzoyl-Q-W-A-V-G-H-L-M-NH2 (AMBA) was synthesized and radiolabeled. The human prostate cancer cell line PC-3 was used to determine the binding (Kd), retention, and efflux of 177Lu-AMBA. Receptor specificity was determined by in vitro autoradiography in human tissues. PK and radiotherapy studies were performed in PC-3 tumor-bearing male nude mice. RESULTS 177Lu-AMBA has a high affinity for the GRP-R (Kd, 1.02 nmol/L), with a maximum binding capacity (Bmax) of 414 fmol/10(6) cells (2.5 x 10(5) GRP-R/cell). Internalization was similar for 177Lu-AMBA (76.8%), 177Lu-BBN8 (72.9%), and 125I-[Tyr4]-BBN (74.9%). Efflux was markedly lower for 177Lu-AMBA (2.9%) compared with 177Lu-BBN8 (15.9%) and 125I-[Tyr4]-BBN (46.1%). By receptor autoradiography, Lu-AMBA binds specifically to GRP-R (0.8 nmol/L) and to the neuromedin B receptor (NMB-R) (0.9 nmol/L), with no affinity for the bb3 receptor (>1,000 nmol/L). 177Lu-AMBA was renally excreted (55 %ID 1 h [percentage injected dose at 1 h]); tumor uptake at 1 and 24 h was 6.35 %ID/g and 3.39 %ID/g, respectively. One or 2 doses of 177Lu-AMBA (27.75 MBq/dose) significantly prolonged the life span of PC-3 tumor-bearing mice (P < 0.001 and P < 0.0001, respectively) and decreased PC-3 tumor growth rate over controls. When compared using World Health Organization criteria, mice receiving 2 doses versus 1 dose of 177Lu-AMBA demonstrated a shift away from stable/progressive disease toward complete/partial response; by RECIST (Response Evaluation Criteria in Solid Tumors), median survival increased by 36% and time to progression/progression-free survival increased by 65%. CONCLUSION 177Lu-AMBA binds with nanomolar affinity to GRP-R and NMB-R, has low retention of radioactivity in kidney, demonstrates a very favorable risk-benefit profile, and is in phase I clinical trials.

[1]  Donald L. Hayes,et al.  Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr = 2,3-diaminopropionic acid and X = H2O or P(CH2 , 2003, Cancer research.

[2]  J. Edwardson,et al.  Fates of endocytosed somatostatin sst2 receptors and associated agonists. , 1998, The Biochemical journal.

[3]  W. Oyen,et al.  Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. , 2001, European journal of nuclear medicine.

[4]  T. Reynolds,et al.  Bombesin Receptors in the Brain , 1996, Annals of the New York Academy of Sciences.

[5]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[6]  B. Göke,et al.  Binding, internalization, and processing of bombesin by rat pancreatic acini. , 1991, The American journal of physiology.

[7]  H. Friess,et al.  Bombesin Receptors in Distinct Tissue Compartments of Human Pancreatic Diseases , 2000, Laboratory Investigation.

[8]  J. Millar,et al.  Chronic desensitization to bombesin by progressive down-regulation of bombesin receptors in Swiss 3T3 cells. Distinction from acute desensitization. , 1990, The Journal of biological chemistry.

[9]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[10]  Ryan Park,et al.  microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  T. Visser,et al.  Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  E P Krenning,et al.  [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. , 2001, European journal of nuclear medicine.

[13]  Michael Ljungberg,et al.  Evaluation of parameters influencing S values in mouse dosimetry. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  A. Schally,et al.  Characterization of high‐affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC‐3 and DU‐145: Internalization of receptor bound 125I‐(Tyr4) bombesin by tumor cells , 1994, The Prostate.

[15]  Joonyoung Kim,et al.  MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. , 2003, Bioconjugate chemistry.

[16]  S. Weiner,et al.  End-stage renal disease after treatment with 90Y-DOTATOC , 2001, European Journal of Nuclear Medicine.

[17]  Donald L. Hayes,et al.  Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. , 2003, Nuclear medicine and biology.

[18]  A. Schonbrunn,et al.  Somatostatin pretreatment increases the number of somatostatin receptors in GH4C1 pituitary cells and does not reduce cellular responsiveness to somatostatin. , 1988, The Journal of biological chemistry.

[19]  M. R. Hellmich,et al.  Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. , 2003, Cancer research.

[20]  J. Reubi.  Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.

[21]  J C Reubi,et al.  Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. , 1999, Cancer research.

[22]  T. Visser,et al.  Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  A. Schally,et al.  Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. , 2005, Current pharmaceutical design.

[24]  H. Ohki‐Hamazaki,et al.  Development and function of bombesin-like peptides and their receptors. , 2005, The International journal of developmental biology.

[25]  G. D. Vincentis,et al.  99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  R. Jensen,et al.  Desensitization of neuromedin B receptors (NMB-R) on native and NMB-R-transfected cells involves down-regulation and internalization. , 1994, The Journal of biological chemistry.

[27]  J. Reubi,et al.  Bombesin Receptor Subtypes in Human Cancers: Detection with the Universal Radioligand 125I-[d-TYR6, β-ALA11, PHE13, NLE14] Bombesin(6–14) , 2002 .

[28]  D. Grignon,et al.  Neutron or photon irradiation for prostate tumors: enhancement of cytokine therapy in a metastatic tumor model. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  Martin A Walter,et al.  Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  D. Payan,et al.  Direct Observation of Endocytosis of Gastrin Releasing Peptide and Its Receptor (*) , 1995, The Journal of Biological Chemistry.

[31]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[32]  E. Nitzsche,et al.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  J. Reubi,et al.  Synthesis and Evaluation of Bombesin Derivatives on the Basis of Pan-Bombesin Peptides Labeled with Indium-111, Lutetium-177, and Yttrium-90 for Targeting Bombesin Receptor-Expressing Tumors , 2004, Cancer Research.

[34]  M. Sunday.  Tissue‐specific Expression of the Mammalian Bombesin Gene , 1988, Annals of the New York Academy of Sciences.

[35]  E. Corazziari,et al.  Detection of colon cancer with 99mTc-labeled bombesin derivative (99mTc-leu13-BN1). , 2004, Cancer biotherapy & radiopharmaceuticals.

[36]  A. Schally,et al.  Luteinizing hormone‐releasing hormone antagonist Cetrorelix (SB‐75) and bombesin antagonist RC‐3940‐II inhibit the growth of androgen‐independent PC‐3 prostate cancer in nude mice , 1997, The Prostate.

[37]  T. Visser,et al.  Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  G. Slegers,et al.  Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study , 2000, European Journal of Nuclear Medicine.